Previous 10 | Next 10 |
home / stock / nnbxf / nnbxf news
2023-11-14 13:01:05 ET Nanobiotix S.A. (NBTX) Q3 2023 Earnings Conference Call November 14, 2023, 08:00 AM ET Company Participants Craig West - Senior Vice President of Investor Relations Laurent Levy - Co-Founder and Chief Executive Officer Bart Van Rhijn - Chie...
$2.5 billion global licensing, co-development, and commercialization agreement expands worldwide potential of novel radioenhancer NBTXR3 16.9 months median progression free survival (mPFS) and 23.1 months median overall survival (mOS) following radiotherapy-activated (RT) NBTXR3 in topline St...
PARIS and CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities f...
PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand t...
PARIS and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treat...
PARIS and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treat...
Strategic Collaborator-presented Phase 1 Pancreatic Cancer Data An ongoing Phase 1, collaborator-led study of NBTXR3 in locally advanced pancreatic cancer (LAPC) established a favorable safety profile and recommended dose 23 months median Overall Survival (mOS) observed in 17 ...
Final data from Study 102 Dose Expansion show that radiotherapy-activated NBTXR3 was feasible and well tolerated in elderly patients with a high burden of comorbidity (n=56) Consistently high injected-lesion overall response rate of 81.8% and complete response rate of 63.6% in the evaluable p...
PARIS and CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities ...
Data presented at the 2023 Special Meeting on Pancreatic Cancer of the American Association for Cancer Research Preliminary data show local endoscopic injection of NBTXR3 followed by radiotherapy activation remains feasible with a tolerable safety profile in 15 patients As of t...
News, Short Squeeze, Breakout and More Instantly...
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment 48% ORR in evaluable anti-PD-1 naïve patients (n=25...
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, a...